Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| IL2-C52H6 | Canine | Canine IL-13 R alpha 2 Protein, His Tag (MALS verified) |  |
|
|
| IL2-H82E6 | Human | Biotinylated Human IL-13 R alpha 2 Protein, His,Avitag™ (MALS verified) |  |
|
|
| IL2-R52H5 | Rhesus macaque | Rhesus macaque IL-13 R alpha 2 Protein, His Tag |  |
|
|
| IL2-H5256 | Human | Human IL-13 R alpha 2 Protein, Fc Tag (MALS verified) |  |
|
|
| IL2-HF2H3 | Human | FITC-Labeled Human IL-13 R alpha 2 Protein, His Tag |  |
|
|
| IL2-H52H5 | Human | Human IL-13 R alpha 2 Protein, His Tag (MALS verified) |  |
|
|
Loaded Human IL-13, Fc Tag (Cat. No. IL3-H5256) on Protein A Biosensor, can bind Human IL-13 R alpha 2, His Tag (Cat. No. IL2-H52H5) with an affinity constant of 6.09 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Immobilized Biotinylated Human IL-13 R alpha 2, His,Avitag (Cat. No. IL2-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Monoclonal Anti-IL-13 R alpha 2 Antibody, Mouse IgG1 with a linear range of 0.4-2 ng/mL (QC tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| MB-101 (Mustang Bio) | MB-101 | Phase 1 Clinical | Mustang Bio Inc, City Of Hope National Medical Center | Glioblastoma; Central Nervous System Neoplasms; Brain Neoplasms; Glioma | Details |
| IL13Ralpha2 CAR-T cell therapy (Jonsson Comprehensive Cancer Center) | Phase 1 Clinical | Uclas Jonsson Comprehensive Cancer Center | Solid tumours; Medulloblastoma; Ependymoma; Skin Melanoma; Pheochromocytoma; Squamous Cell Carcinoma of Head and Neck; Adenoma, Islet Cell; Adenocarcinoma of Lung; Glioblastoma; Neuroendocrine Tumors; Uveal melanoma; Adrenocortical Carcinoma; Breast Neoplasms; Thyroid Neoplasms; Paraganglioma; Melanoma | Details | |
| IL13Rα2 targeted CAR-T cell(Yooyoung) | YYB-103; CLM-103 | Phase 1 Clinical | YooYoung Pharmaceutical Co Ltd | Glioma; Amyotrophic Lateral Sclerosis | Details |
| IL13Rα2 CAR-T cell therapy(TCRCure Biopharma) | Phase 1 Clinical | Tcrcure Biopharma Ltd | Glioma | Details | |
| MT-026 | MT-026 | Phase 1 Clinical | T-Maximum Pharmaceutical (Suzhou) Co Ltd | Glioma | Details |
| SNC-109 | SNC109; SNC-109 | Phase 1 Clinical | Shanghai Simnova Biotechnology Co Ltd | Glioblastoma | Details |
This web search service is supported by Google Inc.
A-Z
